Nutriband Chairman to Present at NobleCon21 Investor Conference
TL;DR
Nutriband's conference presentation offers investors early insights into their abuse-deterrent fentanyl patch technology for potential market advantage.
Nutriband Chairman Serguei Melnik will present at NobleCon21 on December 3, with a webcast available the following day through nobleconference.com and Channelchek.com.
Nutriband's AVERSA technology prevents abuse of transdermal drugs, making medication safer for patients and communities worldwide.
Nutriband's innovative abuse-deterrent patch technology transforms how potent medications are delivered through the skin safely.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference, on December 3 at 9:30 a.m. Eastern time. The presentation will take place at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida, providing investors with insights into the company's pharmaceutical development pipeline.
Investors and guests may attend the conference at a discounted rate using code NTRBNOBLECON, making the event more accessible to current and potential shareholders. For those unable to attend in person, a high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days, ensuring extended accessibility for the investment community.
The company's primary focus is the development of a portfolio of transdermal pharmaceutical products, with their lead product being an abuse-deterrent fentanyl patch incorporating their proprietary AVERSA technology. This technology represents a significant advancement in pharmaceutical safety, as it can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
This presentation comes at a critical time for pharmaceutical companies developing abuse-deterrent technologies, as the opioid crisis continues to be a major public health concern worldwide. The development of technologies like AVERSA could have substantial implications for patient safety and drug regulation, potentially setting new standards for how controlled substances are delivered through transdermal methods.
For investors seeking additional information about Nutriband, the company maintains its corporate website at www.nutriband.com, though the company notes that any material contained in or derived from their websites is not part of the official press release. The conference presentation provides an opportunity for the investment community to gain deeper insights into Nutriband's technology platform and development timeline directly from company leadership.
Curated from InvestorBrandNetwork (IBN)
